Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

American Society of Clinical Oncology (ASCO) - Tập 17 Số 2 - Trang 485-485 - 1999
Joanne L. Blum1, Stephen E. Jones1, Aman U. Buzdar1, Patricia LoRusso1, Irene Kuter1, Charles L. Vogel1, B Osterwalder1, Hans Ulrich Burger1, C. Brown1, T. Griffin1
1From the Physician Reliance Network (PRN) Research, Baylor-Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, and M.D. Anderson Cancer Center, Houston, TX; Harper Hospital, Detroit, MI; Massachusetts General Hospital, Boston, MA; Cancer Center, North Miami Beach, FL; and Hoffman-LaRoche, Inc, Nutley, NJ.

Tóm tắt

PURPOSE: Capecitabine is a novel, oral, selectively tumor-activated fluoropyrimidine carbamate. This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine at 2,510 mg/m2/d given for 2 weeks followed by a 1-week rest period and repeated in 3-week cycles, in patients with paclitaxel-refractory metastatic breast cancer. PATIENTS AND METHODS: Patients were to have received at least two but not more than three prior chemotherapeutic regimens, one of which had to have contained paclitaxel given for metastatic disease. One hundred sixty-three patients were entered onto the study at 25 centers, and 162 patients received capecitabine. One hundred thirty-five patients had bidimensionally measurable disease, and 27 patients had assessable disease. RESULTS: The overall response rate was 20% (95% confidence interval, 14% to 28%). All responding patients were resistant to or had failed paclitaxel, and all had received an anthracycline. Three complete responses were seen, with complete response durations of 106, 109, and 194+ days. Median duration of response was 8.1 months, median survival time was 12.8 months, and the median time to disease progression was 93 days. The most common treatment-related adverse events were hand-foot syndrome, diarrhea, nausea, vomiting, and fatigue. Diarrhea (14%) and hand-foot syndrome (10%) were the only treatment-related adverse events that occurred with grade 3 or 4 intensity in more than 10% of patients. CONCLUSION: Capecitabine is an active drug in the treatment of paclitaxel-refractory metastatic breast cancer. It has a favorable toxicity profile with the added advantage of being an oral drug administered at home.

Từ khóa


Tài liệu tham khảo

Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685,1998-690,

Jones A, Harris AL: New developments in angiogenesis: A major mechanism for tumor growth and target for therapy. Cancer J 4:209,1998-217,

10.1016/S0006-2952(97)00682-5

Twelves C, Budman DR, Creaven PJ, et al: Pharmacokinetics and pharmacodynamics of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 15:479,1996, (abstr)

10.1200/JCO.1998.16.9.2977

10.1200/JCO.1998.16.5.1795

Valero V, Burris HA, III Jones SE, et al: Multicenter pilot study of Taxotere in Taxol-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 15:107,1996, (abstr)

10.1007/s002800050551

10.1200/JCO.1997.15.4.1395

10.1200/JCO.1995.13.8.2056

10.1200/JCO.1995.13.12.2886

10.1016/0277-5379(88)90046-6

Anderson JR, Cain KC, Gelber RD, et al: Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treatment Rep 69:1139,1985-1144,

10.1200/JCO.1983.1.11.710

10.1093/jnci/87.17.1316

10.1200/JCO.1997.15.6.2403

10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G

10.1200/JCO.1984.2.3.187

10.1001/jama.1994.03510440069036

10.1007/s002800050432

10.1200/JCO.1997.15.1.110

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 17 Số 2

485-485

Thông tin tác giả